Relevance of Raynaud’s in Systemic Sclerosis

Save

Raynaud’s phenomenon (RP) is integral to the diagnosis and management of systemic sclerosis (SSc) patients; a recent analysis suggests that RP should be characterized based on color change and the presence of other symptoms to know whether RP portends more serious manifestations.

RNL 2022: Spondyloarthritis Spectrum

Save

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.

- Microbiome in Spondyloathritis - Jose Scher, MD

- Axial Psoriatic Arthritis - Philip Mease, MD

- Juvenile Spondyloathritis - Pamela Weiss, MD

Rising Incidence of Systemic Lupus Erythematosus

Save

Data from Olmstead county, MN over the past four decades shows that the incidence and prevalence of systemic lupus erythematosus (SLE) is increasing.

SLE was diagnosed using the EULAR/ACR criteria and looked at patients seen between 1976–2018.

Methotrexate Monitoring (5.13.2022)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.

Wiki Guidelines Approach to Pyogenic Osteomyelitis

Save

A crowd sourced, WikiGuidelines approach to clinical treatment guideline development for pyogenic osteomyelitis yielded 7 important clinical questions, 2 clear treatment recommendations and 5 topic reviews to inform future treatment or investigations.

Arthritis Predicts Hepatic Fibrosis in Hemochromatosis

Save

Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis. 

Is Alzheimer's Risk Lower With TNF Inhibitors?

Save

Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Save

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

Consequences of TNF inhibition (3.18.2022)

Save

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Seropositivity Linked to Bronchiectasis in Rheumatoid Arthritis

Save

Rheumatoid arthritis associated bronchiectasis (RA-BR) is uncommon, and is unrelated to interstitial lung disease (ILD), but like ILD, can substantially impact RA outcomes.

Efficacy and Safety of Mavrilimumab in Giant Cell Arteritis

Save

A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against granulocyte-macrophage colony-stimulating factor [GM-CSF]) is capable of inducing clinical remission.

RheumNow Live is Coming to Town (3.11.2022)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Could Anifrolumab Work in Lupus Nephritis?

Save

Anifrolumab is effective and FDA approved for use in systemic lupus erythematosus (SLE); and now, a trial in lupus nephritis that almost shows benefit.

Kawasaki Disease Guideline from ACR and Vasculitis Foundation

Save

The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of

ACR Guidelines for the Treatment of Systemic Juvenile Idiopathic Arthritis

Save

The ACR has updated its clinical guidelines for the management of juvenile idiopathic arthritis (JIA), with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA (with and without macrophage activation syndrome); only the latter, systemic JIA recommendations are reported he

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

ACR Addresses Racial Disparities in Lupus Trials

Save

The American College of Rheumatology (ACR) is launching two new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Educatio

RheumNow Podcast - RWCS 2022 Roundup (2.19.2022)

Save

Drs. Jack Cush and Artie Kavanaugh review the highlights of the RWCS (Rheumatology Winter Clinical Symposium) from Maui.

Predicting Treatment Response in Inflammatory Muscle Disorders

Save

Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.